Ontak
(denileukin diftitox)PreclinicalBiologic
EisaiDenileukin diftitox is used to treat a type of blood cancer called cutaneous T-cell lymphoma, where cancer cells affect the skin. It works by targeting and destroying these cancer cells.[1] Ontak is currently being investigated across 4 indications[3], with its most advanced program in Preclinical.[1]
Ontak is one of 38 biologic programs targeting Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma. It is currently in Preclinical.
4
Indications
24
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
19 competitors in Cutaneous T-Cell Lymphoma
#DrugCompanyPhaseTrials
1Adcetris
PfizerApproved
Trexall
Jazz PharmaceuticalsApproved
Targretin
BBausch Health Americas, Inc.
Approved
Adriamycin
PfizerApproved
Venclexta
AbbVieApproved
Tecfidera
BiogenApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Beleodaq
AAcrotech Biopharma Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphoma7 trials
Melanoma2 trials
Leukemia2 trials
Metastatic Melanoma2 trials
Phase II Trial of Ontak With Metastatic Melanoma
Completed·—·Phase 2·NCT00299689·69 enrolled
10 more indications
Induction Therapy1 trial
Renal Cancer1 trial
Chronic Lymphocytic Leukemia1 trial
Non-Small Cell Lung Cancer1 trial
Fallopian Tube Cancer1 trial
Relapse1 trial
Denileukine Diftitox for Relapsed ALCL
Withdrawn·—·Phase 2·NCT00801918
Transplantation1 trial
Treatment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for denileukin diftitox. EMBL-EBI & Wellcome Sanger Institute.
- [4]